Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals, (“Salix”), are one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced its presence at the European Association for the Study of the Liver’s (EASL) International Liver Congress™ (ILC) 2022 through the presentation of new XIFAXAN® (rifaximin) data that was selected for inclusion in the program. ILC 2022 is being held virtually and in-person in London, the United Kingdom, from June 22-26, 2022. The data will be presented in the Cirrhosis and its complications session on Saturday, June 25, 2022.
“As a leading pharmaceutical company specializing in hepatology, Salix continues to invest in research and development to address the scientific and clinical unmet needs in liver disease. We continue our close collaboration with the medical community to advance the treatment of life-threatening conditions such as overt hepatic encephalopathy (OHE), and improve the standard of care and quality of life of liver patients. To this end, the work to be presented at EASL highlights the fact that early identification and management of OHE precipitating factors is an important component of an overall disease management strategy to reduce the risk of OHE recurrence and HE-related hospitalizations,” said Tage Ramakrishna, M.D., chief medical officer and president of Research & Development, Bausch Health.
The research to be featured at ILC 2022 and available via the meeting’s online platform is as follows:
XIFAXAN
- Bajaj, Jasmohan S. et al. “Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose” Poster #SAT517
